VASCADE MVP®

Vascular Closure for EP Procedures

Early Ambulation. Simple. Proven.

Simple & Easy to Use 0% Major Complications in 1,223 Patients in 5 EP Clinical Trials¹⁻⁵


Designed for EP Procedures. Proven by EPs.




Early Ambulation

AMBULATE Clinical Trial¹

Prospective, Multicenter Randomized 1:1 Clinical Trial



	n=199 limbs	n=209 limbs	
Major Complications	0%	0%	-
Minor Complications	1.0%	2.4%	0.456



Proven

Proven by EPs in AMBULATE Clinical Trial¹ and AMBULATE Same Day Discharge Clinical Studies²⁻⁵

Prospective multicenter studies of same day discharge in paroxsymal and persistent AF ablation patients Simple & Easy to Use 0% Major Complications in 1,223 Patients in

EP Clinical

Frials¹

Using the VASCADE MVP[®] System



91.2% Discharged the Same Day (SDD)

99.7% SDD Succss with no access site complications⁷

0% ZERO (0) major complications⁸

Ordering Information

PRODUCT	CATALOG NUMBER	DESCRIPTION	QUANTITY
VASCADE MVP [®] Venous Vascular Closure System (VVCS)	800-612C-10U	6–12F Inner Diameter (15F maximum outer diameter)	1 box (10 devices per box)

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 – 12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

The VASCADE MVP Venous Vascular Closure System (VVCS) Model 800-612C is also indicated for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

The VASCADE MVP Venous Vascular Closure System (VVCS) should not be used in patients with a known allergy to bovine derivatives.

Hover your camera over the QR code to learn more about VASCADE MVP.



Please consult product labels and instructions for use for indications, contraindications, warnings, precautions and adverse events. See VASCADE MVP IFU 3972 Instructions for Use.

For a list of worldwide office locations and contact information, visit: www.haemonetics.com/officelocations

Learn More: 800-537-2802 CustomerServiceNA@haemonetics.com hospital.haemonetics.com/vascular-closure/vascade-mvp

1. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. JACC Clin Electrophysiol 2020; 6(1):111-124.

 Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system VASCADE MVP following multi-access cardiac ablation procedures. J Cardiovasc Electrophysiol 2021. 32(2): 191-99.
 AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781

- AMDDCATE date bay Discharge fregistry fredospective orday. No rosoboror
 4/5. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. Published online Nov 30, 2022. J Cardiovasc Electrophysiol https://doi.org/10.1111/jce.15763
- P-values from 2-sided Wilcoxon rank-sum test for medians, unadjusted for stratification factor.
- 7. Venous access site closure-related complications through 15-day follow up
- 8. Major venous access site closure-related complications through 15-day follow up

@ 2018, 2023 Haemonetics Corporation. Haemonetics and VASCADE MVP are trademarks or registered trademarks of Haemonetics Corporation in the U.S., other countries or both. 03.2023 USA. LIT 4344 Rev DA

